Status:

COMPLETED

Comparison Between Initial Routine PICC and General IV Access in Terminally Ill Cancer Patients

Lead Sponsor:

Pusan National University Yangsan Hospital

Conditions:

Peripherally Inserted Central Catheter

Intravenous Access

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

To establish the IV access strategy for terminally ill cancer patients, using comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group...

Detailed Description

Reliable intravenous (IV) access is an important issue in terminally ill cancer patients, however, they have limited or no peripheral venous access due to edema or long period of IV therapy. Thus, int...

Eligibility Criteria

Inclusion

  • Cancer patients with histologically or cytologically confirmed malignancy and fulfilled all of the following conditions
  • Patients with expected survival time of 3 months or less due to a progressive disease without additional anticancer treatment. (However, palliative radiation treatment for symptom control is allowed.)
  • Patients who need the IV access route continuously for hydration or medication.
  • Age18 or older
  • Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed about all pertinent aspects of the trial prior to enrollment

Exclusion

  • Patients who showed severe coagulopathy such as thrombocytopenia (Platelet count ≤ 20,000/mm2) or international normalized ratio (INR) prolongation (≥2.0 ) in spite of treatment
  • Patients who have an evidence of current sepsis (bacteremia or fungemia)
  • 'current' means bacteremia/fungemia without eradication on follow-up peripheral blood culture
  • patients with persistent fever (bacteremia or fungemia cannot be ruled out)
  • Patients who is impracticable to PICC insertion due to uncontrolled behavioral disorders

Key Trial Info

Start Date :

May 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2020

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT03299868

Start Date

May 1 2017

End Date

June 30 2020

Last Update

August 25 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Pusan National University Yangsan Hospital

Yangsan, Gyeongsangnam-do, South Korea, 50612